Literature DB >> 20441428

Mechanisms of action of intravenous immunoglobulins.

Anne Baerenwaldt1, Markus Biburger, Falk Nimmerjahn.   

Abstract

Intravenous immunoglobulin (IVIg) has been used for nearly three decades as an efficient anti-inflammatory therapeutic regimen in a growing number of autoimmune diseases. Despite this their success in clinical application, the mechanism of action of IVIg therapy remains elusive. During the last few years, several mechanisms dependent on either the IgG variable or constant fragment have been proposed to explain the potent immunomodulatory activity of IVIg. This review will discuss which molecular and cellular pathways might be involved in the anti-inflammatory activity of IVIg and for which types of autoimmune diseases they might be relevant.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20441428     DOI: 10.1586/eci.10.9

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  13 in total

1.  Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis.

Authors:  Dilip K Challa; Uta Bussmeyer; Tarique Khan; Héctor P Montoyo; Pankaj Bansal; Raimund J Ober; E Sally Ward
Journal:  MAbs       Date:  2013-06-19       Impact factor: 5.857

2.  GM-CSF and IL-4 are not involved in IVIG-mediated amelioration of ITP in mice: a role for IL-11 cannot be ruled out.

Authors:  B J B Lewis; D Leontyev; A Neschadim; M Blacquiere; D R Branch
Journal:  Clin Exp Immunol       Date:  2018-09       Impact factor: 4.330

3.  Inhibitory effect of IVIG on IL-17 production by Th17 cells is independent of anti-IL-17 antibodies in the immunoglobulin preparations.

Authors:  Mohan S Maddur; Meenu Sharma; Pushpa Hegde; Sébastien Lacroix-Desmazes; Srini V Kaveri; Jagadeesh Bayry
Journal:  J Clin Immunol       Date:  2012-08-07       Impact factor: 8.317

4.  A comparative structural and bioanalytical study of IVIG clinical lots.

Authors:  Annamaria Sandomenico; Valeria Severino; Angela Chambery; Annalia Focà; Giuseppina Focà; Claudio Farina; Menotti Ruvo
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

Review 5.  Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target.

Authors:  Sanjay W Pimplikar
Journal:  J Clin Immunol       Date:  2014-04-08       Impact factor: 8.317

Review 6.  Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.

Authors:  P Mark Hogarth; Geoffrey A Pietersz
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

7.  Intravenous immunoglobulins modulate neutrophil activation and vascular injury through FcγRIII and SHP-1.

Authors:  Jung-Eun Jang; Andrés Hidalgo; Paul S Frenette
Journal:  Circ Res       Date:  2012-03-13       Impact factor: 17.367

8.  Intravenous immunoglobulin protects neurons against amyloid beta-peptide toxicity and ischemic stroke by attenuating multiple cell death pathways.

Authors:  Alexander Widiapradja; Viktor Vegh; Ker Zhing Lok; Silvia Manzanero; John Thundyil; Mathias Gelderblom; Yi-Lin Cheng; Dale Pavlovski; Sung-Chun Tang; Dong-Gyu Jo; Tim Magnus; Sic L Chan; Christopher G Sobey; David Reutens; Milan Basta; Mark P Mattson; Thiruma V Arumugam
Journal:  J Neurochem       Date:  2012-04-27       Impact factor: 5.372

9.  Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation.

Authors:  Fabian Käsermann; David J Boerema; Monika Rüegsegger; Andreas Hofmann; Sandra Wymann; Adrian W Zuercher; Sylvia Miescher
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

10.  Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia.

Authors:  Theresa Guhr; Judith Bloem; Ninotska I L Derksen; Manfred Wuhrer; Anky H L Koenderman; Rob C Aalberse; Theo Rispens
Journal:  PLoS One       Date:  2011-06-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.